12th Jun 2014 12:24
LONDON (Alliance News) - Shares in Physiomics PLC surged Thursday, after it said it has signed a head of terms agreement for a new collaboration with Diatech Pharmacogenetics srl.
The Oxford-based systems biology company said that, under the terms of the expected collaboration agreement, the two companies will together develop an innovative in-silico platform to personalise cancer patient treatment.
The company said it expects the new in-silico platform to combine pharmacological information related to cancer drugs with genomic and physiological information about the patient, to predict which treatments and regimens will increase the chance of recovery.
It said the platform will initially be used to support physicians to make the best choice of available treatment options for patients, but said the software could also be further developed to choose the right patient groups for clinical trials of new drugs.
Physiomics said that both parties anticipate signing a full collaboration agreement within the next six months.
Physiomics shares were up 8.6% Thursday afternoon at 0.190 pence.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics